News and Insights

Developing a Robust Portfolio

Managing Portfolios to Deliver Economic and Clinical Value

Applied Clinical Trials

Economic and clinical value has become the basis for both differentiation and maintaining premium pricing, and the importance of the economic and clinical value case is likely only to increase. This trend is truly global in scope, applies to multiple key stakeholder groups (payers, physicians, and patients), and is particularly…

Market Segmentation in the New Healthcare Landscape


Increasingly, pharmaceutical companies are being asked – if not required – to demonstrate that their products deliver economic and clinical value to a wide range of stakeholders, including payers, providers, pharmacy benefit managers (PBMs), and patients.  In the past, regulatory approval alone was sufficient to successfully bring a new product…

The Bullish Outlook for Biosimilars

BioPharm International

There are several important reasons for stakeholders to be optimistic about prospects for biosimilars. During the past few years, questions about the underlying technology and market acceptance have begun to resolve themselves in a positive manner. Regulatory pathways are being defined, and major players and investments are lining up. Most…

Marrying Big Data with Personalized Medicine

BioPharm International

Global healthcare systems are currently undergoing major transformations spurred by increasing regulation, record public debt and shrinking budgets. The U.S. has the dubious distinction of leading the way in this regard. The mandates of the Affordable Care Act, along with shrinking reimbursement to providers are fundamentally changing the operation of…

The Affordable Care Act’s Impact on Innovation in Biopharma

BioPharm International

The Affordable Care Act (ACA) has elicited intense national debate and sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward.  Within this uncertain market, what is obvious is that the industry is in the midst of significant…